About what are the leading healthcare services stocks?
Leading stocks led the market. These include WuXi AppTec, Myriad Medical and Zhifei Bio. With their strong R&D strength, leading technology and solid performance, these companies have become popular targets for investors. The following editorial brings about what are the leading stocks in medical services, which are of great benefit to you, take a look together.
What are the leading stocks in medical services
The leading stocks in medical services concept are:
1, Tongze Medical (600763): the leading medical services. Tongze medical 2021 third quarter total operating income rose 14.62% year-on-year to 819 million yuan. Has Kunming Maternal and Child Healthcare Reproductive Medicine Hospital Co., Ltd, mainly engaged in assisted reproduction medical services; funded the establishment of three leaves children's dental chain management Co., Ltd, positioning high-end children's dental market segments.
2, Aier ophthalmology (300015): medical services leader. Aier Ophthalmology 2021 Q3 quarterly report shows that total operating income increased -3.48% year-on-year to 4.248 billion yuan, net profit increased 2.05% year-on-year to 888 million yuan. 2013, Aier Ophthalmology Hospital Group and the Central South University jointly set up a professional ophthalmology medical school - Central South University Aier Ophthalmology College, mainly to train master's and doctoral ophthalmologists, and to train ophthalmologists. It mainly cultivates senior medical talents with master's and doctoral degrees in ophthalmology; in 2014, it once again jointly established the Aier College of Ophthalmology and Optometry with Hubei University of Science and Technology.
3, Guoxin Health (000503): is a state-owned enterprise in the medical service industry.
4, ST Huapu (000509): the company's main business, medical services and bulk commodity trade. International medicine (000516): in April 2015, the company and Ali cloud, Donghua software signed a strategic cooperation agreement, will *** with the creation of China's first entity of the "hospital of the future" - Xi'an International Medical Center, which is also the first data-driven precision medical care, health management of the entity's medical institutions.
5, Jinling Pharmaceutical (000919): a drug production, sales business, drug production business, refers to the production of proprietary Chinese medicines, chemical drugs; drug sales business, refers to the self-produced drugs and agents of the sale of drugs, medical equipment and so on.
What are the leading stocks of Chinese medicine stocks
1 Pientzehuang
2 Yunnan Baiyao
3 Jiuzhitang
4 Tongrentang
5 Baiyunshan
6 JiangZhongPharmaceutical
7 Ma Yinglong
What are the leading stocks of medical beauty listed companies
1, Huaxi Biological: leading stocks of medical beauty. Huaxi biological latest offer 164.65 yuan, 7 days within the share price fell 0.23%; this year's rise fell -12.85%, the price-earnings ratio of 121.96. The world's leading, microbial fermentation of hyaluronic acid production technology as the core of the high-tech enterprises, hyaluronic acid industrialization scale ranked in the forefront of the international community, the company is the earliest realization of the microbial fermentation method of production of hyaluronic acid one of the enterprises;; the company is the earliest realization of microbial fermentation method of production of hyaluronic acid; the company is one of the enterprises. In June 2020, the company intends to 290 million yuan to acquire 100% of the equity of Dongying Foset, Foset is mainly engaged in the production and sale of hyaluronic acid raw materials, the construction of hyaluronic acid series of products with a leading level of production equipment.
2, love beauty: medical beauty leading stocks. Aimer's latest offer 565.91 yuan, 7 days within the stock price fell 0.59%; this year's rise fell -13.13%, the price-earnings ratio of 125.54. Domestic injectable hyaluronic acid leader, solution injection products revenue accounted for 63.07%, which burst the product hi body performance is strong, the overall gross profit margin of up to 92.17%, higher than Maotai, pure medical beauty leading stocks.
3, international medicine: in the investor interactive platform, said, as of now, the company's construction projects are mainly for the rehabilitation hospital project. The company has carried out medical beauty, orthopedics, reproductive business belongs to the listed company.
4, Aoyuan beauty valley: the company to green fiber as a link, will be in high-end textiles, medical beauty, health and sanitation applications such as exploration, especially will rely on the controlling shareholder China Aoyuan Group in Shanghai Oriental Beauty Valley (one of the domestic medical beauty, make-up, health industry base) of the strategic layout.
5, Suning Global: the next 2 ~ 3 years is expected to medical beauty net profit of 50 million +, the current four organizations have not been consolidated. The company's 2022 net profit of 1.5 billion yuan of net income from the mother of consensus expectations, accounting for 3.3%. Huashen science and technology: medical beauty hospital project is still in progress.
6, DZH: the company's holding subsidiary Han peptide biological is carrying out the development, production and sales of medical beauty products.
7, Tongze medical (600763): medical services leader. Tongze medical 2021 third quarter total operating income increased 14.62% year-on-year to 819 million yuan. Owns the Kunming Maternal and Child Healthcare Reproductive Medicine Hospital Co., Ltd, mainly engaged in assisted reproduction medical services; funded the establishment of three leaves children's dental chain management Co., Ltd, positioning high-end children's dental market segments.
Healthcare sector leading stocks
Hengrui Medicine
600276
Shanghai
Chemical Pharmaceuticals
It is China's innovative drug research and development of the first and leader. It is a leading company in China's innovative drug field with a complete product mix and R&D channels. It is a leader in innovative drug development. Piratinib is independently developed by the company 1. An innovative drug is the company's heavy bomb product. Piratinib has a $1.4 billion market for breast cancer indications, and future indications will be expanded to include lung and stomach cancer.
Fosun Pharma
600196
Shanghai
Biopharmaceuticals II
Fuhong Hanklin is a platform for the research and development and production of biopharmaceuticals, and owns 61.093 shares of the company, with biosimilars leading the way in China in terms of research and development strength and progress. It is expected that biosimilars such as rilituximab, trastuzumab and adalimumab will be approved in the next three years. The biosimilars market is large, with many heavyweight products, high barriers to entry and low Medicare support. In the long run, they are optimistic about the oligopoly competition model.
Yunnan Baiyao
000538
Shenzhen
Chinese Medicine II
The company is one of China's leading manufacturers of proprietary Chinese medicines. It is one of the top 50 proprietary Chinese medicine companies. The company's main products include Yunnan Baiyao and natural botanicals, with 19 dosage forms and more than 300 varieties, and its sales volume ranks first in Yunnan Province. At present, the company also owns Yunnan Baiyao Bulk and Yunnan Baiyao Capsules, which are national-level protected proprietary Chinese medicines.On August 18, 2017, Yunnan Baiyao was selected into the 2017 China Health Brand List and Brand Value List.
Xinlitai
002294
Small and medium-sized board
Chemical Pharmaceuticals
Shenzhen Litai Pharmaceuticals Co. Ltd. internal and external expansion, is a double force in the medical equipment ladder. The company focuses on the development of cardiovascular specialty drugs, innovative drugs and unique products. Existing patented drugs have unique advantages, forming a pyramid product structure radiating from high-end to downward. Innovative drugs are progressing well and clinical use of flucytosine is in progress. The novel anti-heart failure drug S glucagon-like peptide-1-Fc injectable fusion protein has been accepted.
Kellettin
600166
Shanghai
Chemical Pharmaceuticals
Kellettin Pharmaceuticals Group (Tianjin) Co., Ltd. is dedicated to the technological innovation and commercial use of global pharmaceutical technologies, and provides comprehensive pharmaceutical outsourcing services to mainstream international pharmaceutical companies. Its scope mainly includes clinical stage new drug development, preparation and marketed drugs. Process optimization and large-scale production take place at the commercialization stage. Domestic CMOs engage in custom R&D and custom life one-stop services through CDMOs, providing many domestic pharmaceutical companies with Class 1.1 new drug R&D services; representative new drugs: treatment of hepatitis C, cardiovascular diseases, gallbladder fibers and so on.
Aier Ophthalmology
600418
Shanghai
Medical Services
The company is one of the largest ophthalmology medical institutions in China. Aier Eye Hospital Group Ltd. is an eye care provider. The company mainly provides patients with ophthalmic medical services, such as diagnosis, treatment of various eye diseases, optometry and dispensing glasses.In 2008 and 2009, the company stood out among China's Most Valuable Companies in 2008 and 2009, and was listed in the Top 50 Most Valuable Companies in China for Zero Technology for two consecutive years.
Pientzehuang
600436
Shanghai
Chinese Medicine II
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. is a company which mainly produces and sells medical products such as ingots, tablets, granules and other medical products as well as tourism products. At present the main business at present is the production and sale of traditional Chinese medicine. In recent years, daily necessities and cosmetics are growing rapidly. The Company's new strategy of one core and two wings is based on the production of traditional Chinese medicine, with healthcare medicines, health food, functional beverages, specialty cosmetics, and daily chemical products as the two wings, supplemented by the distribution of pharmaceutical products. The company will take Pientzehuang, a strong brand with a hundred-year history, as the basis to open the way for the future growth of branded Chinese medicine consumer products.
What are the Leading Stocks in Medical Plate
1.General Pharmaceutical Leader:600276 Hengrui Medicine
Hengrui Medicine is a large-scale pharmaceutical listed company integrating scientific research, production and sales, and it is the largest scientific research and production base of anti-tumor drugs and surgical drugs in China, and one of the most innovative large-scale pharmaceutical enterprises in China at present. It is the largest scientific research and production base of antitumor drugs and surgical drugs in China, and is currently one of the most innovative large-scale pharmaceutical enterprises in China. The company's main products include antitumor drugs, cardiovascular drugs, surgical drugs, endocrine drugs and so on.
2. Chinese medicine leader: 000538 Yunnan Baiyao
Yunnan Baiyao Group Co., Ltd. formerly known as Yunnan Baiyao Factory was founded in 1971, is the largest, strongest and best brand of pharmaceutical enterprise groups in Yunnan Province. The company's business includes research, production and sales of chemical raw materials, chemical preparations, proprietary Chinese medicines, Chinese herbal medicines, biological products, health food, cosmetics and beverages; it is also involved in the fields of medical devices and daily chemical products.
3.Blood products leader:002007 Hualan Bio
Hualan Bio, founded in 1992, is a national key high-tech enterprise engaged in the research, development and production of blood products. 1998, Hualan Bio became the first enterprise in China to pass the GMP certification of blood products industry. As a national designated large-scale biological products manufacturer, Hualan Bio has strong technological development strength, leading technology level, first-class production and testing equipment, scientific and standardized management, and perfect quality assurance system, and is in the leading position among domestic enterprises in the same industry.
4. Vaccine leader: 300122 Zhifei biological
Zhifei biological is mainly engaged in biotechnology development and management, research, production and sales as one of the high-tech companies.
5. Pharmaceutical R&D leader: 603259 WuXi AppTec
We are a company that provides a full range of integrated new drug R&D and production services. The company is committed to promoting the new drug R&D process, and its services cover chemical drug R&D and manufacturing, cell and gene therapy R&D and manufacturing, medical device testing and other fields. WuXi AppTec's empowerment platform is carrying R&D and innovation projects from more than 5,200 partners in more than 30 countries around the world, and is committed to bringing more new and better medicines to patients around the world and realizing the vision of "making the world free of difficult medicines and complicated diseases" as soon as possible.
6. Medical Device Leader:300760Myriad Medical
Myriad Medical is China's leading R&D and high-tech medical device manufacturer, and one of the world's medical device innovation leaders. The company is committed to R&D and clinical medical device manufacturing, and its products cover four major areas: life information and support, clinical examination and reagents, digital ultrasound and radiography. The company insists on investing about 10% of its annual turnover to support product innovation and R&D. It has established an R&D management platform that is synchronized with the international first-class level, and its R&D management process is in line with CE, FDA standards and ISO system.